Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million
Basel, Switzerland, February 09, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba® (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a milestone payment to Basilea of USD 10 million.
Basilea is entitled to receive milestone payments upon Pfizer’s cumulative Cresemba sales in Pfizer’s licensed territories exceeding certain thresholds. Pfizer is currently commercializing Cresemba in many European countries, including France, Germany, Italy, Spain and the U.K, as well as in a number of countries in the Asia Pacific region. Under the agreement, sales milestones totaling USD 12 million were triggered in 2019 and regulatory and commercial milestones totaling around USD 6 million were triggered in 2020.
David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased that the continued strong sales performance of Cresemba has now triggered the 10 million US dollar milestone from Pfizer. This confirms that Cresemba is addressing a high medical need and we look forward to making our important antifungal treatment available to patients in a rapidly increasing number of countries around the world.”
In November 2017, Basilea and Pfizer extended their existing license agreement for Europe (excluding the Nordics), Russia, Turkey and Israel, to include China, including Hong Kong and Macao, and sixteen countries in the Asia Pacific region. Under the agreement with Pfizer, Basilea is still eligible for regulatory and sales milestone payments of up to approximately USD 620 million, in addition to receiving mid-teen royalties on sales.
Cresemba is currently marketed in around 50 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. For the twelve-month period to the end of September 2020, total "in-market" sales of Cresemba amounted to USD 244 million, a more than 28 percent growth year-on-year.1
About isavuconazole (Cresemba)
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.2 Cresemba is also approved in the United States and several additional countries in Europe and beyond.3 It has orphan drug designation in the U.S., Europe and Australia for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.
Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This press release can be downloaded from www.basilea.com.
- IQVIA, September 2020. In-market sales reported as moving annual total (MAT) in U.S. dollars corrected for currency fluctuations.
- European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: February 08, 2021]
- The registration status and approved indications may vary from country to country.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS9.3.2021 11:30:00 CET | Press release
AuctionAuction resultsAuction date2021-03-09Maturity2024Tendered volume, SEK mln1000 +/- 1000Offered volume, SEK mln700Volume bought, SEK mln200Number of bids3Number of accepted bids2 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln05000100Volume bought, SEK mln000100Number of bids0101Number of accepted bids0001Average yield, %---0.18Lowest accepted yield, %---0.18Highest yield, %---0.18Accepted at lowest yield, %---100 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln010000Volume bought, SEK mln010000Number of bids0100Number of accepted bids0100Average yield, %-0.137--Lowest accepted yield, %-0.137--Highest yield, %-0.137--Accepted at lowest yield, %-100--
RESULT OF RIKSBANK CERTIFICATE SALE9.3.2021 10:15:00 CET | Press release
AuctionAuction resultsAuction date2021-03-09Start date2021-03-10Maturity date2021-03-17Interest rate, %0.00 %Offered volume, SEK bn380.0Total bid amount, SEK bn1888.6Accepted volume, SEK bn380.0Number of bids16Percentage alloted, %20.121 %
Results Extraordinary General Meeting9.3.2021 08:30:00 CET | Press release
PRESS RELEASE: Amsterdam – 9 March 2021.Intertrust N.V. (“Intertrust”) [Euronext: INTER], a global leader in providing tech-enabled corporate and fund solutions to clients operating and investing in international business, announces that in the Extraordinary General Meeting (EGM) of 8 March 2021 the shareholders adopted all voting items on the agenda. Chief Executive Officer Shankar Iyer was appointed as member of the Management Board of Intertrust. Mr. Iyer’s appointment has been approved by Dutch regulators and is effective immediately, for a first term of four years. At the EGM a total of 74.32% of the total issued share capital was represented. The results of the votes for each item on the agenda, will be published on our website https://www.intertrustgroup.com/investors/shareholder-information/extraordinary-general-meeting-march-2021/. Draft minutes of the EGM will be published no later than three months after the end of the meeting, after which shareholders should have the opport
Van Lanschot Kempen: update on share buy-back programme 2 March 2021 – 8 March 20219.3.2021 08:30:00 CET | Press release
Amsterdam/’s-Hertogenbosch, the Netherlands, 9 March 2021 In the period from 2 March 2021 until 8 March 2021 Van Lanschot Kempen has repurchased 16,381 of its own shares (depositary receipts for Class A ordinary shares). The shares were repurchased at an average price of €21.80 per share for a total amount of €358,433. These repurchases are part of the share buy-back programme for at most 400,000 of own shares, which was announced on 25 February 2021. The total number of shares repurchased to date is 41,381. More information, including a detailed overview of the repurchase transactions under this programme, is available on www.vanlanschotkempen.com/sharebuyback. Media Relations: +31 20 354 45 85; email@example.com Investor Relations: +31 20 354 45 90; firstname.lastname@example.org About Van Lanschot Kempen Van Lanschot Kempen, a wealth manager operating under the Van Lanschot, Kempen and Evi brand names, is active in Private Banking, Asset Management and Me
GrandVision publishes Annual Report 2020 and convocation for virtual AGM9.3.2021 08:00:00 CET | Press release
GrandVision publishes Annual Report 2020 and convocation for virtual AGM Schiphol, the Netherlands - 9 March 2021. GrandVision N.V. (EURONEXT: GVNV) today announced that it has published its Annual Report 2020 including the Financial Statements 2020. The Annual Report is available for download and in digital form on GrandVision’s website: annualreport2020.grandvision.com. GrandVision has also published the convocation for the Annual General Meeting of Shareholders (AGM) on its website (www.grandvision.com). The AGM will be held on 23 April 2020. Due to the continued impact of the COVID-19 pandemic, the meeting will be held virtually, and shareholders will not be able to attend the AGM in person at a physical location. By using this format, GrandVision is following recommendations to forgo major events and to protect the health of shareholders, employees and all other stakeholders. Details of how shareholders can exercise their shareholder rights under these special circumstances are se
Kalmar receives repeat order of AutoStrads from Patrick Terminals9.3.2021 08:00:00 CET | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 9 MARCH 2021 AT 9 AM (EET) Kalmar, part of Cargotec, is to supply a total of twelve new Kalmar AutoStrad™ units to Patrick Terminals. The order for the fully automated straddle carriers was booked in Cargotec's 2021 Q1 order intake, with delivery of the machines scheduled to be completed during Q2 of 2022. Patrick Terminals is Australia's leading container terminal operator, handling over three million TEUs annually. The company operates some of Australia's most technologically advanced terminals at four strategically located ports: Brisbane AutoStrad Terminal, Sydney AutoStrad Terminal, Melbourne Terminal and Fremantle Terminal in Western Australia. In November 2019 Patrick Terminals signed a comprehensive software maintenance and support agreement with Kalmar covering the equipment automation systems at Brisbane and Sydney. Of the twelve new 8th generation Kalmar AutoStrads, five will operate at Brisbane and seven at Sydney. The machines are part
Ahold Delhaize share buyback update9.3.2021 08:00:00 CET | Press release
Zaandam, the Netherlands, March 9, 2021 – Ahold Delhaize has repurchased 1,693,300 of Ahold Delhaize common shares in the period from March 1, 2021 up to and including March 5, 2021. The shares were repurchased at an average price of €21.93 per share for a total consideration of € 37.1 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020. The total number of shares repurchased under this program to date is 11,368,600 common shares for a total consideration of € 262.9 million. Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.